US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.

CONCLUSIONS: Secukinumab significantly improved disease severity and PROs after 6 months of follow-up in this real-world study, which is consistent with other current real-world studies. PMID: 31035822 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31035822?dopt=Abstract

Source: Journal of Dermatological Treatment - May 1, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research